Skip to main content

Table 3 Frequency of NPAEs in P. vivax malaria patients given tafenoquine/chloroquine, primaquine/chloroquine or placebo/chloroquine [9]

From: Neurological and psychiatric safety of tafenoquine in Plasmodium vivax relapse prevention: a review

Adverse event, n (%)TQ + CQPQ + CQ (N = 50)Placebo + CQ (N = 54)
50 mg (N = 55)100 mg (N = 57)300 mg (N = 57)600 mg (N = 56)
Any nervous system disorder17 (31)17 (30)13 (23)16 (29)17 (34)21 (39)
 Headache14 (25)17 (30)10 (18)16 (29)14 (28)20 (37)
 Dizziness7 (13)2 (4)5 (9)4 (7)5 (10)5 (9)
 Migraine000001 (2)
 Tremor001 (2)1 (2)00
 Paraesthesia0001 (2)00
 Sciatica01 (2)0000
 Burning sensation1 (2)00000
 Syncope00001 (2)0
 Dysaesthesia00001 (2)0
Any psychiatric disorder2 (4)3 (5)5 (9)3 (5)1 (2)1 (2)
 Insomnia2 (4)3 (5)5 (9)3 (5)3 (6)1 (2)
 Tic0001 (2)00
Expanded termsa
 Asthenia5 (9)4 (7)1 (2)5 (9)00
 Fatigue01 (2)1 (2)000
  1. CQ chloroquine, PQ primaquine, TQ tafenoquine
  2. aExpanded terms: labyrinthitis, vertigo, vestibular disorder, asthenia, fatigue, and alcohol intolerance were also considered with possible reference to vestibulocochlear function